Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | HRAS G12X |
| Gene Variant Detail | |
| Relevant Treatment Approaches | MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor PI3K Inhibitor (Pan) PIK3CA inhibitor PIK3CB inhibitor PIK3CD inhibitor PIK3CG inhibitor RAS Inhibitor (Pan) |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| HRAS G12X | pancreatic ductal adenocarcinoma | sensitive | RAS Inhibitor (Pan) | Daraxonrasib | Phase III | Actionable | In a Phase III trial (RASolute 302), treatment with Daraxonrasib (RMB-6236) in patients with metastatic pancreatic ductal adenocarcinoma significantly improved median overall survival (mOS, 13.2 vs 6.6 months, HR=0.40, p<0.001) and median progression-free survival (mPFS, 7.3 vs 3.5 months, HR=0.45, p<0.001) compared to chemotherapy in patients harboring RAS G12X, and mOS (13.2 vs 6.7 months, HR=0.40, p<0.001) and mPFS (7.2 vs 3.6 months, HR=0.49, p<0.001) in the overall cohort (PMID: 42223072; NCT06625320). | 42223072 |